Afasevikumab

• Description:

  Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities[1].

• Product Name Alternative:

  RG 7624; RO 5553110; NI-1401

• UNSPSC:

  12352203

• Target:

  Interleukin Related

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/afasevikumab.html

• Purity:

  95

• Solubility:

  10 mM in DMSO

• Smiles:

  [Afasevikumab]

• Molecular Weight:

  (146.065 kDa)

• References & Citations:

  [1]Andrea Chiricozzi, et al. Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential. Psoriasis (Auckl) . 2019 May 24;9:29-35.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  No Development Reported

• CAS Number:

  [1589503-30-9]